We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Valirx Plc | LSE:VAL | London | Ordinary Share | GB00BLH13C52 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.15 | -4.62% | 3.10 | 3.00 | 3.20 | 3.25 | 3.10 | 3.25 | 155,187 | 09:33:42 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Medical Laboratories | 0 | -2.37M | -0.0262 | -1.24 | 2.93M |
From May 2019 to May 2024
TIDMVAL
RNS Number : 9600H
ValiRx PLC
30 March 2020
ValiRx Plc
("ValiRx" or the "Company")
Update
London, UK . 30 March 2020: ValiRx Plc (AIM: VAL), a clinical stage biotechnology company, provides the following update:-
The Company remains critically short of working capital and as previously stated is dependent on the ongoing support of its creditors in order to continue trading.
The Company adjourned its General Meeting which was to be held on 25 March 2020 as a result of the COVID-19 situation.
The Company is reviewing options available to it in order to reconvene the meeting, bearing in mind the current restrictions on public gatherings.
The Company is in discussions with a number of potential funders who have indicated conditional willingness to invest in the Company in the event that resolutions are passed.
There is no guarantee that resolutions will be passed by shareholders at the General Meeting or that funding will ultimately be available to the Company or that creditors will be willing to extend their support to enable potential funding to occur. A further announcement will be made in due course.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For more information, please contact:
Hot Features
Premium
ValiRx plc Tel: +44 (0) 20 7073 2628
www.valirx.com
Dr Satu Vainikka, Chief Executive Tel: +44 (0) 20 7073 2628
Tarquin Edwards, Head of Communications. Tel: +44 (0) 7879 458
364
tarquin.edwards@valirx.com
Cairn Financial Advisers LLP - Nominated
Adviser
Liam Murray / Jo Turner Tel: +44 (0) 20 7213 0880
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
UPDDGGDXXSDDGGC
(END) Dow Jones Newswires
March 30, 2020 02:00 ET (06:00 GMT)
1 Year Valirx Chart |
1 Month Valirx Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
